Loading...

Investors & Media

Investors & Media / News Releases / Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

March 4, 2019

WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it will present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 1:30 p.m. Eastern Standard Time at The Boston Marriott Copley Place in Boston.

The presentation will be given by Apellis founder and chief executive officer Cedric Francois, MD, PhD, and will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the Company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.

Media Contact:
Tully Nicholas
tnicholas@denterlein.com  
617.482.0042  (office)
860.490.0218  (mobile)

Investor Contact:
Alex Kaneakane@w2ogroup.com
212.301.7218  (office)
929.400.2691  (mobile)

Apellis logo.jpg

 

Source: Apellis Pharmaceuticals, Inc.

Apellis logo
© Apellis Pharmaceuticals 2019. | Privacy Policy